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PURPOSE. Uveal melanoma (UM) is fatal in up to 50% of patients because of liver metastases
that are refractory to therapies currently available. While murine xenograft models for human
uveal melanoma are available, they have limited utility for screening large compound libraries
in drug discovery studies. Therefore, new robust preclinical models are needed that can
efficiently evaluate drug efficacy for treatment of this malignancy.
METHODS. Uveal melanoma cell lines generated from primary tumors (92.1, Mel270) and
metastases (OMM2.3, OMM2.5, OMM1) were injected into the yolk of 2-day-old zebrafish
embryos. After 6 days, proliferation and active migration was quantified via automated
confocal image analysis. To determine the suitability of this xenotransplantation model for
drug testing, drugs with three different activities (dasatinib, quisinostat, and MLN-4924) were
added to the water of uveal melanoma–engrafted embryos.
RESULTS. All tested UM cell lines proliferated and migrated in the embryos; significant
differences could be discerned between cell lines: Cells derived from metastases showed
more migration and proliferation than cells derived from the primary tumors, and provided
preclinical models for drug testing. Addition of the Src-inhibitor dasatinib in the water of
engrafted embryos reduced proliferation and migration of high Src-expressing 92.1 cells, but
did not affect low Src-expressing metastatic OMM2.3 cells. Two experimental anticancer
drugs, quisinostat (a histone deacetylase inhibitor) and MLN-4924 (neddylation pathway
inhibitor), blocked migration and proliferation of 92.1 and OMM2.3.
CONCLUSIONS. We established a zebrafish xenograft model of human uveal melanoma with
demonstrated applicability for screening large libraries of compounds in drug discovery
studies.
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Uveal melanoma (UM) is the most common primaryintraocular malignancy in adults and accounts for 5% of
all melanomas.1 This melanoma originates from the uvea,
which includes the choroid, the ciliary body, and the iris.2
Unlike cutaneous melanoma, UM is not induced by mutations
in BRAF, NRAS, or KIT.3 Mutations in the G-proteins GNA11 and
GNAQ present the driver mutations in uveal melanoma,
resulting in activation of the mitogen-activated protein kinases
(MAPK) pathway, among others.4,5 Recent studies show that
the transcriptional coactivator YAP is stimulated by the mutated
G-proteins through Trio-Rho/Rac signaling, and that it is an
essential factor in mutation-driven uveal melanoma growth.6,7
Up to 50% of patients with uveal melanoma may develop
metastases and the prognosis of patients with metastasized
tumors is poor: Median survival is approximately 10 to 18
months.8 Mutations in the BAP1 gene, encoding a ubiquitin
hydrolase, have been associated with the development of
metastases.9,10 Because of the limited efficacy of current
treatments, new therapeutic strategies need to be developed.11
Xenotransplantation of uveal melanoma cells has been already
successfully applied to immunodeficient mice and rabbits.12,13
However, these studies are time consuming and costly. There is
a clear need to develop more efficient in vivo models that can
be used in preclinical testing and in medium- to high-
throughput assays for screening libraries of compounds in
drug discovery studies.
The zebrafish may be an excellent model system for this
purpose, due to several useful properties.14 There are the
general benefits such as relatively low housing costs, a large
clutch size, ex utero development, transparency, and easy
manipulation of the embryo. Specifically focusing on cancer,
zebrafish models have the benefit of a high conservation of
(proto-)oncogenes and tumor suppressor genes between
zebrafish and humans, making the zebrafish model ideal for
identifying clinically relevant genes and compounds.15 In
addition, zebrafish form tumors with similar histopathological
and gene-profiling features as human tumors.16 Important for
our current study, the adaptive immune system in zebrafish
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does not reach maturity until 4 weeks post fertilization,17,18
allowing circumvention of graft rejection by using zebrafish in
embryonic stages. This has been used previously to permit
xenotransplantation with human tumor cells, including cuta-
neous melanoma cells, without immunosuppression.19–21
Moreover, the optical transparency of zebrafish, in combina-
tion with the availability of various tissue-specific fluorescent
reporter transgenic lines, allows detection of tumor develop-
ment within 1 week, and offers unique possibilities for high
resolution, noninvasive live imaging of fluorescently labeled
cancer cells.22–25 Furthermore, zebrafish can absorb small
molecular weight compounds from water, enabling easy
delivery and efficient screening of large numbers of anticancer
compounds.26
The objective of the present study was to determine whether
we can use zebrafish embryos to develop a human uveal
melanoma model that allows for rapid, preclinical anticancer
drug discovery. A panel of five uveal melanoma cell lines was
injected into the yolk of 2-day-old zebrafish embryos, and
proliferation and migration was monitored for 6 days. To
determine suitability for drug screening, the xenograft model
was tested with three different anticancer drugs. We used the
second generation dual BCR-ABL/Src inhibitor dasatinib because
Src has been reported to be activated in a subset of UM cells.27
Furthermore, we used two broad-spectrum cancer inhibitors:
quisinostat and MLN-4924. MLN-4924 is an inhibitor of the
neddylation pathway, which is essential for the activity of the
cullin-RING subtype of the ubiquitin ligases: It blocks turnover of
a subset of proteins, resulting in S-phase defects leading to cell
apoptosis.28 Quisinostat is an experimental pan-inhibitor of
histone deacetylase (HDAC) enzymatic activity, currently in
phase II trials.29
We report that the behavior of the primary and metastatic
uveal melanoma cells in this zebrafish xenograft model
correlates with their grade of malignancy in humans and that
the zebrafish provides a fast, sensitive in vivo vertebrate model
for identifying anticancer compounds to combat uveal
melanoma metastases.
MATERIALS AND METHODS
Animal Care and Handling
We used TG(fli1:EGFP) transgenic zebrafish30 expressing EGFP
in endothelial cells in a wild-type background; zebrafish were
maintained according to standard protocols (http://ZFIN.org,
in the public domain), in compliance with the Dutch animal
welfare regulations. The research followed the statement or
the use of animals in ophthalmic and visual research as
published by the Association for Research in Vision and
Ophthalmology.
Cell Culture
Five human UM cell lines were investigated. Two uveal
melanoma cell lines derived from primary tumors (92.1,
Mel270) and three from UM metastases (OMM1, OMM2.3,
OMM2.5). Cell line OMM1 was derived from a uveal melanoma
skin metastasis, and cell lines OMM2.3 and2.5 were obtained
from a liver metastasis in the same patient from which cell line
Mel270 was derived. Cell line 92.1 was established in the
Leiden University Medical Center laboratory, Leiden, The
Netherlands.31 Cell lines Mel270, OMM2.3, and OMM2.5 came
from the Schepens Eye Research Institute, The Massachusetts
Eye and Ear Infirmary, Harvard Medical School, Boston32;
OMM1 cells were kindly provided by G PM Luyten (Rotterdam
University Hospital/LUMC, Leiden, The Netherlands).33 Cells
mentioned above were cultured in 1:1 RPMI-1640 medium þ
Dulbecco’s modified Eagle’s medium (DMEM)-F12 (Invitrogen,
Carlsbad, CA, USA) with 10% of fetal calf serum at 378C and 5%
CO2. Human diploid foreskin VH10 fibroblasts were grown in
DMEM supplemented with 10% fetal calf serum. Cell lines were
transduced with lentiviral vector CMV-mCherry-Puro (provided
by RC Hoeben, LUMC) and selected with puromycin. In short,
cells were seeded into 6-well plates 1 day before transduction,
at a density of ~3 3 105 cells/well. The next day, cells were
transduced O/N with the mCherry-expressing lentivirus, with
multiplicity of infection ~1.5, in the presence of 8 lg/mL
polybrene. One day later, the virus-containing medium was
replaced with fresh growth medium. Selection of transduced
cells was started 24 hours later by addition of 0.5 lg/mL
puromycin. Transduction of the cells with the mCherry-Puro
virus did not noticeably change the growth properties of the
cells.
Cell Line Authentication
Cell line identity was validated by short tandem (STR)-DNA
fingerprinting using the AmpF‘STR Identifier kit according to
manufacturer instructions (Applied Biosystems, Carlsbad, CA,
USA). We compared the STR profiles to known fingerprints,34
which can be found in Supplementary Table S1.
Western Blotting
Cells were lysed in Giordano buffer (50 mM Tris-HCl, pH 7.4,
250 mM NaCl, 0.1% Triton X-100, 5 mM EDTA) with protease-
and phosphatase inhibitors. Proteins (15–20 lg total protein
lysates) were separated by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis, blotted onto commercial mem-
branes (Immobilon-P; Millipore Corp., Billerica, MA, USA),
incubated with appropriate primary and secondary antibodies,
and bands were visualized by chemoluminescence (West Dura;
Pierce Biotechnology, Rockford, IL, USA). Antibodies used
were: Anti-p53 (DO-1, 1:500; Santa Cruz Biotechnology,
Heidelberg, Germany); Phospho-Src Family (Tyr416) rabbit
polyclonal antibody and Src (36D10) rabbit mAb (1:1000; Cell
Signaling Technology, Danvers, MA, USA); anti-MAPK, activat-
ed, diphosphorylated ERK-1 and 2, (1:1000; Sigma-Aldrich
Corp., St. Louis, MO, USA); p44/42 MAPK (ERK1/2; 137F5)
rabbit mAb (1:1000; Cell Signaling Technology); anti-cyclin E
(HE12, 1:250; Santa Cruz Biotechnology); anti-p27 KIP1 (Y239,
1:1000; Abcam, Cambridge, UK); anti-p21/WAF1/Cip1 (CP74,
1:500; Millipore Corp.); anti-acetyl K9-Histone 3 (cat. #06-599,
1:2000; Upstate/Millipore Corp.) and anti-Vinculin (hVIN1,
1:1000; Sigma-Aldrich Corp.).
Crystal Violet Staining for Cell Survival
Cells were seeded in triplicate in 96-well plates: 2500 cells/well
in a total volume of 135 lL medium. Next day, treatment with
compounds was started by adding 15 lL of a 310 concentra-
tion. After 72 hours, cell survival was determined by fixating
and staining the cells with crystal violet (0.1%) for 30 minutes.
After rinsing with water, crystal violet was solubilized in 100%
methanol and absorbance (545 nm) was measured in a
microplate reader (Victor3 Multilabel Counter 1420-042;
Perkin-Elmer, Wellesley, MA, USA).
Human Cancer Cell Implantation
Before implantation, eggs were kept at 288C and manually
dechorionated at 1 day post fertilization (dpf). Cells were
grown to 60% to 90% confluency, trypsinized (0.25% trypsin/
0.53 mM EDTA), centrifuged for 5 minutes at 200g, washed
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with Dulbecco’s phosphate-buffered saline (DPBS; Invitrogen),
and taken up in 7lL 2% polyvinylpyrrolidone-40 (PVP-40,
Calbiochem, San Diego, CA, USA). Cell suspensions were
injected using glass capillary needles (1 mm OD 3 0.78 mm ID;
Harvard Apparatus, Holliston, MA, USA) with an approximate
opening equal to the dimension of one cell. At 2 dpf, embryos
were anesthetized with 0.003% tricaine (Sigma-Aldrich Corp.)
and positioned on a 10-cm Petri dish coated with 1% agarose.
Approximately 400 to 500 cells were injected into the yolk sac,
using a pneumatic pico pump and a manipulator (World
Precision Instruments, Sarasota, FL, USA). The number of
injected cells was determined by counting cells present per
droplet of cells after injection on agarose and monitoring the
consistency of droplet size after injection in the fish. The
number of cells injected was highly consistent, as observed
during regular verification of the amount of cells per droplet
on agarose. At 1 day post injection (dpi), embryos with cells
injected into the circulation were discarded. After the
implantation, embryos were kept in egg water (60 lg/mL
OceanSalt in demi water) at 348C. This temperature was
chosen as an intermediate between 378C (optimal cell
temperature) and 288C (optimal fish temperature), which
allows for normal development of the embryo20 while not
impairing UM growth. At 6 dpi, embryos were fixed overnight
with 4% paraformaldehyde (PFA) at 48C.
In Vivo Toxicity/Treatment With Chemical
Compounds
The tested compounds were: dasatinib (BMS-354825; Cayman
Chemicals, Ann Arbor, MI, USA); quisinostat (JNJ-26481585;
Johnson & Johnson Pharmaceutical R&D, New Brunswick, NJ,
USA); and MLN-4924 (Nedd8-activating enzyme inhibitor;
LifeSensors, Malvern, PA, USA).
To test compound toxicity, six 3-dpf embryos were placed
per well into a 24-well plate containing 1 mL egg water, in
which the compound was diluted at different concentrations.
The embryos were kept at 348C. Medium was refreshed every
FIGURE 1. Migration of the uveal melanoma cancer cells outside the yolk of zebrafish embryos. (A) Uveal melanoma cells (OMM1) stably expressing
mCherry. (B) Site of injection in a 2-dpf embryo. (C) Embryo 2 dpf TG(fli1:EGFP) with green vasculature, injected with UM cells (OMM1, red), at 1
dpi. At 6 dpi, the injected embryos show active migration of (D) Mel270 and (E) OMM2.3, respectively, in the tail region and in the head. According
to these stereo images, the cells can migrate through the host circulation and invade the surrounding tissues. Size and location of tumor masses in
92.1, OMM1 and OMM2.5 cell lines are comparable with OMM2.3. Data are representative stereo fluorescent images (original magnification: 320) of
>10 independent experiments.
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day and survival was checked up to 8 dpf. The compound was
considered nontoxic for survival rates higher than 80%.
To analyze the effect of treatment, cancer cells were
implanted in the yolk sac at 2 dpf. At 1 dpi, treatment was
started on implanted embryos, with experimental conditions
identical to the toxicity tests. Embryos at 6 dpi were fixed with
4% PFA and stored at 48C.
Microscopy and Image Analysis
Stereo images were taken with a fluorescence stereo micro-
scope (Leica M205FA; Leica Microsystems, Inc., Buffalo Grove,
IL, USA). Confocal images were acquired using a confocal
microscope (Leica Microsystems, Inc., or NIKON3, 34 lens;
NIKON Corp., Tokyo, Japan). Live embryos were anesthetized
with 0.003% tricaine (Sigma-Aldrich Corp.) and kept in egg
water. Fixed embryos were embedded in a layer of 1.5% methyl
cellulose diluted in egg water, 1% low melting agarose or 0.1%
PBS-T, and imaged in glass-bottom 96-well plates. Image
processing was performed with ImageJ 1.43 (http://imagej.
nih.gov/ij/; provided in the public domain by the National
Institutes of Health, Bethesda, MD, USA). Image analysis
(ImagePro Analyzer 7.0; Media Cybernetics, Rockville, MD,
USA) was performed with a macro developed in our laboratory,
as described previously.35 In brief, this macro is able to detect
each individual red fluorescent cluster inside the embryo and
quantify its distance from the site of implantation. The mean
distance from the site of implantation for each tumor cell
cluster was used to measure the migration of cancer cells in a
single embryo (mean migration). Additionally, the mean
proliferation readout was estimated per embryo by the
multiplication of the mean area of all tumor foci with the total
number of red objects (Area*Objects).
Statistics
Statistical analysis was performed using graphing and statistical
software (GraphPad PRISM, version 4.0; GraphPad, San Diego,
CA, USA). Differences between two or more means were
determined using Student’s unpaired t-test and one-way
ANOVA with Dunnett’s posttest. Statistical significance was
indicated in the following way: *P < 0.05, **P < 0.01, and ***P
< 0.001.
RESULTS
Active Migration of UM Cells in Zebrafish Embryos
To determine if the zebrafish is a suitable organism for
modeling UM tumor progression via engraftment, we selected
FIGURE 2. Characterization of migration and proliferation of five UM cell lines in the zebrafish embryonic xenograft model. (A) Quantification of
Area*Objects plotted in the logarithmic scale and of mean migration plotted in linear scale. Each filled symbol in the upper panel indicates the
tumor burden present per embryo, calculated by multiplying the mean area (in pixels) of all the identified foci with the number of red objects
detected. The lower panel indicates the mean distance of migration away from the site of implantation per red object in a single embryo. The data
presented are the results of two repeated experiments for each cell line. The number of embryos for each group are NMel270¼ 50, NOMM2.3¼ 61,
NOMM2.5¼ 55, N92.1¼ 39, NOMM1¼ 85. (B) Scatterplots showing tumor foci dissemination from several embryos injected with each cell line. The
upper graph shows the relation between data point coordinates and fish morphology. For each embryo, the calculated injection site, marked with
an orange cross, is aligned with the 0,0 coordinates on the graph. Statistical analyses performed with one-way ANOVA test followed by Dunnett’s
posttest. **P < 0.01.
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five UM cell lines, labeled them with red fluorescent mCherry
(Fig. 1A), and implanted 400 to 500 labeled cells into the yolk
of 2-dpf TG(fli1:EGFP) embryos with green fluorescent vessels
(Fig. 1B). Embryos were screened at 1 dpi for successful
implantation (>90% for each cell line in every experiment; Fig.
1C). Hematogenous dissemination to the head and tail region
of the zebrafish larvae was detected for all tested cell lines from
4 dpi onward. The cancer cell dissemination was considered as
active migration if the cells were beyond the boundaries with
the heart cavity frontally, on top of the swim bladder dorsally
and beyond the urogenital opening caudally. Migration of cells
out of the yolk was first observed at 4 dpi, and increased at 5
and 6 dpi, at which time approximately 50% of the total
amount of injected embryos had migrating cells. At 6 dpi, a
variation in the amount of cell burden was observed for
different cell lines (Figs. 1D, 1E). Importantly, the primary
tumor-derived Mel270 (Fig. 1D) showed less dissemination
then metastasis-derived OMM2.3 (Fig. 1E). The human foreskin
fibroblasts VH10 did not migrate from the yolk sac (data not
shown). In a previous study, we used 3T3 cells,24 and normal
melanocytes were previously described as less migratory in
comparison with human metastatic melanoma,19 suggesting
that cell dissemination in zebrafish embryo is cancer cell–
specific.
Differential Migration of Primary and Metastatic
UM Cells in the Zebrafish Xenograft Model
In order to quantify the behavior of different UM cell lines in
zebrafish embryos, an automated whole animal bioimaging
assay was applied to confocal microscopy images of fixed 6 dpi
embryos. For quantitative measurements of cell proliferation
and migration, z-stack images were analyzed using a macro
(Media Cybernetics) previously developed in our laboratory.35
Readout of this analysis is seen in Figure 2. All uveal melanoma
cell lines showed migration and proliferation, but differences
between cell lines were observed: primary tumor cell line
Mel270 proliferated and migrated significantly less compared
with metastatic OMM2.3 and OMM2.5 cells, derived from
metastases from the same patient (Figs. 2A, 2B). The tumor
burden induced by Mel270 was significantly lower than the
burden from primary tumor cell line 92.1. In addition, the
metastatic OMM1 cell line migrated more than Mel270, while
proliferation was only slightly, and not significantly, higher than
that of Mel270 (Figs. 2A, 2B).
The scatterplots (Fig. 2B) indicate the localization of all
cancer foci relative to the site of implantation (0;0), using a
different color for each embryo analyzed. The Mel270
scatterplot shows only a few cancer foci which are mainly
clustered close to the yolk area, whereas the other cell lines,
OMM2.3 in particular, are disseminated all through the head
region, the trunk, and the tail.
All together, the results in the embryonic zebrafish
engraftment model are consistent with the clinical behavior
of uveal melanoma in human.
Effects of Dasatinib, Quisinostat, and MLN-4924 In
Vitro
Metastatic OMM2.3 and primary 92.1 UM cell lines in cell
culture were exposed to various concentrations of dasatinib,
an Src tyrosine kinase inhibitor, since previous experiments
showed activation of Src in a subset of UM cell lines.27 In
addition, we used two experimental anticancer drugs: MLN-
4924 and quisinostat.
An in vitro 72-hour treatment with 4 lM dasatinib inhibited
growth of cell line 92.1 by 20% (Fig. 3A). Incubation with MLN-
4924 or quisinostat resulted in strong growth inhibition of both
cell lines, even at the lowest concentration tested, 0.125 lM
and 2.5 nM, respectively (Figs. 3B, 3C). Anticancer drug MLN-
4924 (1 lM) reduced survival of OMM2.3 and 92.1 cells to
approximately 20% (Fig. 3B). The efficacy of quisinostat was
FIGURE 3. Growth inhibition of UM cells in cell culture. We used
mCherry-expressing cell lines Mel270, OMM2.3, and 92.1 in a
proliferation assay as described in the ‘‘Materials and Methods’’
section. Cells were treated for 72 hours with indicated concentrations
of (A) dasatinib, (B) MLN-4924, and (C) quisinostat.
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even more dramatic. At a 10-nM concentration, this drug
completely blocked proliferation of 92.1 and inhibited growth
of OMM2.3 by 80% (Fig. 3C).
Western blot analyses indicated higher basal- and pY416-Src
levels in the untreated 92.1 than in OMM2.3 cells; quantifica-
tion indicated a ~2.5-fold higher level in 92.1 cells. Treatment
with dasatinib efficiently blocked the Y416 phosphorylation
level of Src in both cell lines (Fig. 4A). Interestingly, total levels
of Src increased upon dasatinib treatment. This effect is likely
caused by distinct ubiquitination and degradation of Tyr416-
phosphorylated versus nonphosphorylated Src protein, as has
been published by Harris et al.36
In addition, the protein levels of ERK1/2 and phosphory-
lated ERK1/2 were the same in both cell lines and remained
unchanged after dasatinib treatment.
Figure 4B shows the target proteins affected in 92.1 and
OMM2.3 cells after treatment with quisinostat or MLN-4924.
Interestingly, quisinostat only detectably increased p21 and
p27 levels in 92.1 cells while MLN-4924 elevated p21, p27, and
p53 in both cell types. It should be noted that basal levels of
p21 and p27 are almost undetectable in OMM2.3 cells. In
addition, as expected, quisinostat treatment increased the
acetylation of K9-histone3 in both cell lines. All together, these
data showed that the inhibitors blocked UM cell survival with
distinct activities and via distinct mechanisms.
Toxicity of Dasatinib, Quisinostat, and MLN-4924
The next step was to validate the zebrafish embryonic
xenograft model as described above by analyzing the tumor
response to anticancer drug treatments in vivo. To determine
which concentrations of dasatinib, MLN-4924, and quisinostat
would be well tolerated—with minimal effects on develop-
ment and survival—noninjected embryos were immersed in
these compounds, a well-established method for drug treat-
ment of zebrafish larvae.26,37
Dasatinib was found to be toxic after 4 to 5 days’ exposure
at concentrations higher than 1 lM (Fig. 5A). Neither
quisinostat (Fig. 5B) nor MLN-4924 (Fig. 5C) was toxic to the
embryos, even at the highest concentration tested (1 lM).
Effects of Dasatinib, Quisinostat, and MLN-4924 on
UM Xenografts
After determining the optimal concentration for each chemical
inhibitor, treatments were performed on injected embryos.
Two cell lines were chosen for these experiments: metastatic
OMM2.3, as it was the most aggressive cell line in the zebrafish
embryonic xenograft model, and primary tumor cell line 92.1.
Mel270 cells were not used since basal proliferation and
migration of these cells in untreated embryos were quite low
(Fig. 2).
Embryos injected with OMM2.3- or 92.1-mCherry cells at 2
dpf were treated at 1 dpi with 1 lM dasatinib, and showed a
significantly reduced growth of 92.1 (mean reduction with a
95% confidence interval [MR] was 55.0% 6 25.2%, P < 0.05),
while growth of OMM2.3 cells was not affected (Fig. 6). The
distance of migration from the site of implantation indicates
that treatment with dasatinib significantly reduced dissemina-
tion of 92.1 cells (MRmigration ¼ 29.9% 6 8.5%) and not of
OMM2.3.
The treatment of injected embryos with the broad-spectrum
anticancer drugs MLN-4924 and quisinostat significantly
inhibited both the proliferation and migration of OMM2.3
and 92.1 cells. For anticancer drug MLN-4924, OMM2.3 mean
reductions were as follows: MRgrowth ¼ 46.5% 6 15.4% and
MRmigration ¼ 13.9% 6 5.5%. Compared with OMM2.3, MLN-
4924 inhibited 92.1 growth and migration slightly more:
MRgrowth ¼ 55.9% 6 15.9% and MRmigration ¼ 25.1% 6 7.3%.
Quisinostat was able to inhibit both OMM2.3 (MRgrowth ¼
45.6% 6 16.3%, MRmigration ¼ 13.7% 6 5.5%) and 92.1 cells
(MRgrowth¼ 50.6% 6 15.6%, MRmigration¼ 18.1% 6 7.3%). The
92.1 cells were again slightly more sensitive to quisinostat than
the metastatic OMM2.3 cells, as also seen in the cell culture
(Figs. 3, 7A, 7B). These two drugs seem to have a wider effect
on cancer proliferation compared with the dissemination of
cancer cells in the embryo.
Our results demonstrate that in vivo drug treatment of uveal
melanoma–containing zebrafish inhibited the proliferation of
these tumor cells as observed in vitro, and also reduced the
migration of the UM cells in vivo. However, the zebrafish
model has the distinct advantage of determining the effects of
FIGURE 4. Western blot analysis of proteins from uveal melanoma lines exposed to anticancer drugs (A) 92.1/ and OMM2.3/mCherry cells were
either dimethylsulfoxide (DMSO)-treated (D) or treated with 1 lM dasatinib (Da) for 24 hours. The levels and phosphorylation of Src and ERK1/2
were determined by Western blot analysis. Quantification of Src-levels is indicated underneath the blots. (B) 92.1 and OMM2.3/mCherry cells were
either DMSO-treated (D) or treated with 20 nM quisinostat (Q) or with 1 lM MLN-4924 (M) for 24 hours. Expression of a number of published
targets of MLN-4924 and quisinostat is shown.
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FIGURE 5. Survival of embryos during anticancer compound toxicity testing. Uninjected 3-dpf embryos were placed in 24-well plates exposed to
various concentrations of (A) dasatinib, (B) MLN-4924, and (C) quisinostat and their survival was examined until 8 dpf. n¼ 24; error bars show
standard error of the mean.
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drug treatment on not only the signaling pathways, but also on
tumor growth and metastatic spread, which is not possible
using in vitro screening assays.
DISCUSSION
The prognosis of patients diagnosed with metastatic uveal
melanoma is poor and an effective therapeutic strategy is
lacking. A number of different investigators have used a variety
of immunodeficient mouse strains to develop human-to-mouse
xenograft tumor models to study uveal melanoma.38–42 Tumor
growth was reported within the anterior chamber and vitreous
cavity, with at least one report of metastatic spread of tumors
from the eye to the liver. Investigators have also used direct
injection of tumor cells into the liver to model metastatic liver
tumors. These human uveal melanoma tumor models have
been extremely useful in studies that identify the unique gene
mutations required for malignant transformation of uveal
melanoma. For example, RNAi-mediated depletion of BAP1 in
uveal melanoma cells resulted in reduced tumor growth in
vivo43 and expression of the GNAQQ209L mutation in normal
melanocytes triggered uncontrolled proliferation and malig-
nant transformation in vivo.44 While these mouse tumor
models have been very useful to study specific gene pathways,
they have limited utility for large scale anticancer drug
screening. The most important limitations are: slow tumor
growth and spread, which can take weeks to months; variation
in tumor growth rate; the high cost of breeding and housing
large numbers of mice; and, while tumor growth can be
quantitated in vivo in mice, it is time consuming when
examining large cohorts of mice.
To facilitate the identification of promising new compounds
for treatment of uveal melanoma patients, we describe here the
establishment of a novel uveal melanoma zebrafish engraft-
ment model. In recent years, it has been shown that xenograft
models in zebrafish embryo allow time-effective, dynamic
quantification of tumor burden in vivo. The transparency of the
embryos makes them ideal for noninvasive, high-end micros-
copy, providing the possibility to follow processes such as
angiogenesis and leukocyte infiltration as the tumor progress-
es. Additionally, automated imaging platforms and analysis
software has been developed, permitting rapid imaging of
tumor progression in a large number of embryos. Furthermore,
compounds can be taken up from the water in which the
embryos reside, facilitating screening of single and combined
compounds. Such screening can be done for multiple
xenografted UM cell lines, reflecting the genetic variability of
this cancer and the subsequent differential responses to drugs.
After implantation in the yolk sac of 2 dpf zebrafish
embryos, engrafted uveal melanoma cells successfully migrated
within the embryo body from 4 dpi onward. The automated
quantitative analysis of low-magnification confocal laser
scanning images of 6 dpi fixed embryos revealed phenotypic
differences between UM cell lines that are not evident from
cell culture analysis, with metastatic cell lines behaving more
aggressively in the zebrafish larvae. As these differences may be
correlated with the poor prognosis of UM patients, we
evaluated treatment efficacy of three drugs in both a primary
and a metastatic cell line.
The effect of dasatinib was more pronounced with regard to
migration than proliferation of engrafted 92.1 cells, and
suggests that inhibition of Src phosphorylation mainly controls
cell motility. In both 92.1 and OMM2.3, dasatinib inhibits Src
phosphorylation in an ERK1/2-independent manner. The
resistance of OMM2.3 cells to dasatinib is most likely caused
FIGURE 6. Plots representing area*objects and mean migration of OMM2.3 and 92.1 injected embryos treated with 1 lM dasatinib or DMSO solvent
at 6 dpi. The number of embryos are: for the OMM2.3 groups: NDMSO¼ 26, Ndasatinib¼ 34; and for the 92.1 groups: NDMSO¼ 44 and Ndasatinib¼ 37.
Scatterplots in the right panel visualizing the same data presented in the left panel. Statistical analyses performed with Student’s t-test. *P < 0.05.
**P < 0.01. ***P < 0.001.
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FIGURE 7. Characterization of proliferation and migration of OMM2.3- and 92.1-injected embryos treated with two broad-spectrum cancer
inhibitors: quisinostat and MLN-4924 at 6 dpi. The number of embryos for the OMM2.3 groups: NDMSO¼ 37, NQ¼ 32; for the 92.1 groups: NDMSO¼
41, NQ¼ 34, and for the OMM2.3 groups: NDMSO¼ 37, NMLN¼ 34. Scatterplots in the right panel visualize the same data as presented in the left
panel. Statistical analyses performed with Student’s t-test. *P < 0.05. **P < 0.01. ***P < 0.001.
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by the lower level of Src in this metastasis-derived cell line (Fig.
4A and Maat et al.27).
The administration of the broad-spectrum cancer inhibitors
MLN-4924 and quisinostat to engrafted embryos strongly
inhibited both proliferation and migration of both tested cell
lines. The primary 92.1 cells were more sensitive to MLN-4924
and quisinostat treatment than metastatic OMM2.3 cells. This
was also observed in culture, and suggests that inhibitor
treatment in vivo correlates with treatment in culture.
Although some differences in response regarding upregu-
lation of p21, p27, and p53 are noticed between these two
drugs and the two tested cell lines, the exact mechanism(s) by
which these drugs affect cell cycle progression and survival are
complex and not fully understood. However, because of the
results described here, further investigations on the possible
use of Quisinostat and MLN-4924 for uveal melanoma patients
is warranted.
In summary, this study shows that the here described
zebrafish xenograft model can be used for preclinical analysis
of new anticancer compounds against uveal melanoma in a
time- and cost-effective manner.
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